WO2019210511A1 - 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 - Google Patents

一种s1p1受体激动剂的加成盐及其晶型和药物组合物 Download PDF

Info

Publication number
WO2019210511A1
WO2019210511A1 PCT/CN2018/085617 CN2018085617W WO2019210511A1 WO 2019210511 A1 WO2019210511 A1 WO 2019210511A1 CN 2018085617 W CN2018085617 W CN 2018085617W WO 2019210511 A1 WO2019210511 A1 WO 2019210511A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
salt
crystal form
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2018/085617
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
郑伟
潘武宾
郭家旺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Connect Biopharmaceuticals Ltd
Original Assignee
Suzhou Connect Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US17/052,160 priority Critical patent/US11512078B2/en
Priority to EP24155906.1A priority patent/EP4353719B1/en
Priority to JP2021510499A priority patent/JP7275253B2/ja
Priority to SG11202010969UA priority patent/SG11202010969UA/en
Priority to PCT/CN2018/085617 priority patent/WO2019210511A1/zh
Priority to CA3099196A priority patent/CA3099196A1/en
Priority to EP18917186.1A priority patent/EP3792258B1/en
Priority to NZ770323A priority patent/NZ770323A/en
Priority to IL278464A priority patent/IL278464B2/en
Priority to MX2020011665A priority patent/MX2020011665A/es
Priority to AU2018421487A priority patent/AU2018421487B2/en
Priority to ES18917186T priority patent/ES2978392T3/es
Priority to BR112020022429-4A priority patent/BR112020022429B1/pt
Application filed by Suzhou Connect Biopharmaceuticals Ltd filed Critical Suzhou Connect Biopharmaceuticals Ltd
Priority to KR1020207034174A priority patent/KR102672632B1/ko
Priority to IL312512A priority patent/IL312512B2/en
Priority to KR1020247018420A priority patent/KR20240094023A/ko
Publication of WO2019210511A1 publication Critical patent/WO2019210511A1/zh
Anticipated expiration legal-status Critical
Priority to ZA2020/07347A priority patent/ZA202007347B/en
Priority to US17/961,270 priority patent/US12202822B2/en
Priority to JP2023023091A priority patent/JP7651198B2/ja
Priority to US18/977,539 priority patent/US20250320200A1/en
Priority to JP2025035420A priority patent/JP2025074350A/ja
Priority to IL323665A priority patent/IL323665A/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • This application belongs to the technical field of medicinal chemical preparation and crystallization.
  • a salt form of a drug involved in a disease or condition mediated by the S1P1 receptor and a crystalline form thereof and a method of preparing the salt form or crystal form, a pharmaceutical composition thereof, and use thereof.
  • the compound of formula A has S1P1 receptor agonist activity and selection specificity, and has a significantly shortened in vivo half-life, and thus is a superior second-generation S1P1 receptor agonist.
  • S1P1 receptor agonists that bind to homologous receptors expressed on lymphocytes and cause internalization of the S1P1 receptor, which in turn prevents lymphocyte derivation. Therefore, the S1P1 receptor agonist can reduce the ability of the human body to initiate an immune response by preventing the transport of lymphocytes, and thus can be used as an immunosuppressive agent for treating various autoimmune diseases.
  • the compound of formula A can form a salt with one or more acid compounds of the formula X m H n wherein H is a dissociable hydrogen ion, X is a pharmaceutically acceptable anion, and m and n are Natural numbers; compounds of formula A may also form salts with one or more pharmaceutically acceptable cations, such as alkali metal ions or other pharmaceutically acceptable organic cations.
  • salt formation can improve certain undesirable physicochemical or biopharmaceutical properties of the drug, such as changing the solubility or dissolution of the drug, polymorphism and the like.
  • one of the objects of the present invention is to provide a salt form of a compound of the formula A and a crystalline form thereof, wherein the salt form of the compound of the formula A and its crystal form have one or more improvements. Characteristics, especially in terms of polymorphism, solubility, crystal stability and chemical stability.
  • the salt form of the compound of formula A according to the present invention is hygroscopic, soluble, and thermally stable compared to other conventional salt forms such as potassium salts, calcium salts, hydrochloride salts, citrate salts, and phosphate salts. There are one or more improved properties on the properties (melting point and decomposition temperature).
  • a second object of the present invention is to provide a method for preparing a salt form of the compound of the formula A. Since the compound of the formula A has a low solubility in most solvents and the temperature does not significantly improve the solubility, it is difficult to apply a conventional solution - The solution is mixed to form a salt.
  • the preparation method of the salt type in the invention adopts various methods such as suspension-solution, solid-solution, solid-solid-solvent, suspension-suspension and solid-suspension mixed reaction to form salt, and adopts crystal
  • the type detection method monitors the completeness of salt formation, and the salt formation ratio is confirmed by ion chromatography.
  • the salt form preparation method of the compound represented by the formula A has good handleability in salt formation of a low solubility compound as compared with the conventional salt formation method.
  • a third object of the present invention is to provide a pharmaceutical composition and use of the salt form of the compound of the formula A and its crystalline form.
  • the present invention provides 1- ⁇ 2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]-benzyl ⁇ -
  • the sodium 3-azetidinecarboxylate is a compound formed by a compound of the formula A and a sodium ion in a molar ratio of 1:1, and its structure is as follows:
  • the sodium salt of the compound of formula A of the present invention is substantially crystalline, preferably an anhydride, hydrate or ansolvate. More preferably, in accordance with the purpose of the present invention, there is provided a crystalline form of a sodium salt of a compound of formula A, wherein the X-ray powder diffraction pattern represented by the 2 ⁇ angle has a characteristic peak of 4.4 ⁇ 0.2 at the following position °, 6.6 ⁇ 0.2 °, 14.7 ⁇ 0.2 ° and 17.2 ⁇ 0.2 °.
  • the present invention provides a crystalline form of a sodium salt of a compound of formula A having an X-ray powder diffraction pattern represented by a 2 theta angle having characteristic peaks and their relative intensities at:
  • a typical example of the crystalline form of the sodium salt of the compound of formula A has an X-ray powder diffraction (XRPD) pattern as shown in FIG. More preferably, the Fourier transform infrared spectrum of the crystalline form of the sodium salt of the compound of the formula A is at a wave number of 1560 cm -1 , 1505 cm -1 , 1476 cm -1 , 1417 cm -1 , 1365 cm -1 , 1276 cm -1 , There are characteristic peaks at 885 cm -1 , 849 cm -1 and 756 cm -1 .
  • the present invention provides a process for the preparation of a sodium salt of the compound of the formula A or a crystalline form thereof, the process comprising the steps of: selecting from an alcohol, a ketone, an ether, water, a nitrile or a mixture thereof In the solvent, a compound of the formula A having a molar ratio of 1:1 to 1:5 is mixed with sodium hydroxide and reacted. After completion of the reaction, the solvent is removed and dried.
  • a part of the solvent may be removed first, and then the mixture is cooled and centrifuged to dry the obtained solid; or after the reaction is completed, all the solvent is removed to the solid. The solvent was beaten again and then centrifuged, and the obtained solid was dried.
  • a part of the solvent may be removed first, and after cooling (for example, to room temperature), the solid is precipitated, and the obtained solid is dried.
  • the solvent is selected from the group consisting of methanol, ethanol, acetone, diethyl ether, water, acetonitrile or mixtures thereof.
  • the molar ratio of the compound of the formula A to sodium hydroxide is from 1:1.0 to 1:1.3.
  • the reaction is carried out at 10 to 60 ° C, more preferably at room temperature; preferably, the reaction is carried out under stirring for a period of from 1 to 48 hours, more preferably from 3 to 24 hours.
  • the drying is carried out under vacuum at a temperature of from 10 to 60 ° C, more preferably from 10 to 40 ° C.
  • the drying time is from 1 to 48 hours, more preferably from 1 to 24 hours.
  • the mass-to-volume ratio of the compound of the formula A to the solvent in the preparation method is 1 mg: 1 mL to 50 mg: 1 mL, more preferably 2.5 mg: 1 mL to 41 mg: 1 mL.
  • the "solvent removal” can be accomplished by conventional techniques in the art, such as filtration, volatilization, centrifugation, nitrogen blowing or spin drying; preferably, the solvent is removed by nitrogen blowing, volatilization or filtration; preferably, the “solvent removal”
  • the experimental temperature is 10 to 60 °C.
  • the sodium salt of the compound of the formula A of the present invention has a solubility in water of 10 mg/mL at 25 ° C. Compared with the free state of the known compound of the formula A, the solubility in water is remarkably improved, and the bioavailability is better. degree.
  • the sodium salt of the compound of the formula A of the present invention has a solubility in water of 10 mg/mL at 25 ° C, a calcium salt of the compound of the formula A, a hydrochloride of the compound of the formula A, and a compound of the formula A.
  • the solubility in water is remarkably improved, and the bioavailability is good.
  • the crystalline form of the sodium salt of the compound of the formula A of the present invention is stable under an aqueous system, and therefore has a good application value in a wet granulation or suspension dosage form.
  • the crystal form of the sodium salt of the compound of the formula A of the present invention is allowed to stand at room temperature and a relative humidity of 10% to 90% for 4 months, and its appearance, XRPD and melting point are not changed.
  • the sodium salt of the compound of the formula A of the present invention and the crystal form thereof have good storage stability, and can better avoid the pharmaceutical active ingredient itself and the preparation form containing the sodium salt of the compound of the formula A or its crystal form. Quality, safety, and stability issues in the manufacture and/or storage of drugs, such as impurity crystal forms, solubility differences, and the like.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the sodium salt of the compound of formula A and/or its crystalline form and, optionally, at least one pharmaceutically acceptable carrier or excipient.
  • the invention also provides the use of a sodium salt of the compound of formula A and/or its crystal form for the manufacture of a medicament for the treatment and/or prophylaxis of a disease or condition mediated by the SlP1 receptor.
  • the invention also provides a method for treating and/or preventing a disease or condition mediated by a SlP1 receptor, the method comprising administering to a subject in need thereof a compound of formula A provided herein.
  • a compound of formula A provided herein.
  • Sodium salt and / or its crystal form are preferred.
  • the subject is a mammal; more preferably, the subject is a human.
  • the present invention provides 1- ⁇ 2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]-benzyl ⁇ - 3-azetidinecarboxylic acid sulfate is a compound formed by the compound of the formula A and sulfuric acid in a molar ratio of 2:1, and its structure is as follows:
  • the sulfate salt of the compound of formula A of the present invention is substantially crystalline, preferably an anhydride, a hydrate or an unsolvate. More preferably, in accordance with the purpose of the present invention, there is provided a crystalline form of a sulfate of the compound of formula A, using Cu-K alpha radiation, the crystal form having an X-ray powder diffraction pattern expressed in terms of 2 theta angle in the following position It has characteristic peaks: 5.4 ⁇ 0.2°, 8.1 ⁇ 0.2°, 14.8 ⁇ 0.2°, 16.7 ⁇ 0.2° and 18.3 ⁇ 0.2°.
  • the crystal form of the sulfate of the compound of the formula A has an X-ray powder diffraction pattern represented by a 2 ⁇ angle having characteristic peaks at 5.4 ⁇ 0.2°, 8.1 ⁇ 0.2°, 14.8 ⁇ 0.2°, 15.6 ⁇ 0.2 °, 16.7 ⁇ 0.2 °, 18.3 ⁇ 0.2 °, 21.0 ⁇ 0.2 °, 22.0 ⁇ 0.2 °, 22.9 ⁇ 0.2 °, 25.2 ⁇ 0.2 ° and 26.3 ⁇ 0.2 °.
  • the present invention provides a crystalline form of a sulfate of the compound of Formula A, the X-ray powder diffraction pattern of the crystalline form represented by the 2 ⁇ angle having characteristic peaks and relative intensities at:
  • a typical example of the crystalline form of the sulfate salt of the compound of the formula A has an X-ray powder diffraction (XRPD) pattern as shown in FIG.
  • the Fourier transform infrared spectroscopy of the crystal form of the sulfate of the compound of the formula A is at a wave number of 1733 cm -1 , 1438 cm -1 , 1346 cm -1 , 1230 cm -1 , 1184 cm -1 , 1109 cm -1 , 1063 cm -1 , There are characteristic peaks at 1009 cm -1 , 885 cm -1 , 854 cm -1 and 758 cm -1 .
  • the present invention provides a process for the preparation of a sulfate of the compound of the formula A or a crystalline form thereof, the process comprising the steps of: selecting from an alcohol, a ketone, a cyclic ether, acetonitrile, water or a mixture thereof In the solvent, a compound or a sulfuric acid having a molar ratio of 1:0.4 to 1:10 is formed into a suspension or a solution, and then mixed and reacted. After completion of the reaction, the solvent is removed and dried.
  • a part of the solvent may be removed first, and the obtained solid may be dried by filtration or centrifugation; or all the solvent may be removed after the reaction is completed, optionally The solvent was again added to the solid, and the mixture was centrifuged, and the obtained solid was dried.
  • the solvent in the operation of removing the solvent after completion of the reaction, all the solvent may be removed first, and the mixture is ultrasonically added and then centrifuged to dry the obtained solid.
  • the solvent is selected from the group consisting of methanol, ethanol, n-propanol, acetone, tetrahydrofuran, water, acetonitrile or mixtures thereof.
  • the molar ratio of the compound of formula A to sulfuric acid is from 1:0.4 to 1:7.9.
  • the reaction is carried out at -10 to 60 ° C, more preferably at 10 to 40 ° C; preferably, the reaction is carried out under stirring, and the stirring time is 1 to 72 hours, more preferably 1 to 24 hours. .
  • the drying temperature is from 10 to 60 ° C, more preferably from 10 to 40 ° C.
  • the drying time is from 1 to 48 hours, more preferably from 1 to 24 hours.
  • the mass-to-volume ratio of the compound of the formula A to the solvent in the preparation method is 1 mg: 1 mL to 50 mg: 1 mL, more preferably 4 mg: 1 mL to 35 mg: 1 mL.
  • solvent removal can be accomplished by conventional techniques in the art, such as filtration, volatilization, centrifugation, nitrogen blowing or spin-drying; preferably, the solvent is removed by nitrogen blowing, centrifugation or filtration; preferably, the "removal”
  • the experimental temperature of the solvent is 10 to 60 °C.
  • sulfuric acid means concentrated sulfuric acid having a concentration of 98% by weight, which is commercially available.
  • the sulfate of the compound of the formula A of the present invention has a solubility in water of 25 ⁇ g/mL at 25 ° C, and the solubility in water is more obviously improved compared with the free state of the compound of the formula A, and has a better biological activity. Utilization.
  • the sulfate of the compound of the formula A of the present invention has a solubility in water at 25 ° C of 19 ⁇ g / mL, a calcium salt of the compound of the formula A, a hydrochloride of the compound of the formula A, a compound of the formula A Compared with the conventional salt forms such as citrate and phosphate of the compound represented by the formula A, the solubility in water is remarkably improved, and the bioavailability is good.
  • the sulfate of the compound of the formula A of the present invention has a weight gain of 0.7% in a relative humidity range of 20% to 80%, a potassium salt of the compound of the formula A, a calcium salt of the compound of the formula A, and a formula
  • a potassium salt of the compound of the formula A a calcium salt of the compound of the formula A
  • a formula Compared with the conventional salt forms such as the hydrochloride salt of the compound of formula A, the citrate of the compound of formula A, the phosphate of the compound of formula A, etc., it has a lower hygroscopic weight gain and thus has better storage stability. Sex.
  • the crystal form of the sulfate of the compound of the formula A of the present invention is stable under an aqueous system, and therefore has a good application value in a wet granulation or suspension dosage form.
  • the crystalline form of the sulfate of the compound of the formula A of the present invention is placed under normal, high temperature (60 ° C) and accelerated (40 ° C - 75% relative humidity) conditions for 1 month, and its appearance, XRPD and melting point are not change.
  • the sulfate of the compound of the formula A of the present invention and the crystal form thereof have good storage stability, and can better ensure that the pharmaceutically active ingredient itself and the preparation form of the sulfate containing the compound of the formula A or its crystal form are Quality, safety, and stability issues in the manufacture and/or storage of drugs, such as impurity crystal forms, solubility differences, and the like.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a sulfate salt of the compound of formula A and/or a crystalline form thereof, and optionally at least one pharmaceutically acceptable carrier or excipient.
  • the invention also provides the use of a sulfate salt of the compound of formula A and/or a crystal form thereof for the manufacture of a medicament for the treatment and/or prevention of a disease or condition mediated by the SlP1 receptor.
  • the invention also provides a method for treating and/or preventing a disease or condition mediated by a SlP1 receptor, the method comprising administering to a subject in need thereof a compound of formula A provided herein.
  • a subject in need thereof a compound of formula A provided herein.
  • Sulfate and / or its crystal form Preferably, the subject is a mammal; more preferably, the subject is a human.
  • the present invention provides 1- ⁇ 2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]-benzyl ⁇ - 3-Azetidinecarboxylic acid maleate is a compound formed by the compound of the formula A and maleic acid in a 1:1 molar ratio, and its structure is as follows:
  • the maleate salt of the compound of formula A of the present invention is substantially crystalline, preferably an anhydride, a hydrate or an unsolvate. More preferably, in accordance with the purpose of the present invention, there is provided a crystalline form of a maleate salt of a compound of formula A, using Cu-K alpha radiation, the crystal form having an X-ray powder diffraction pattern expressed in terms of 2 theta angle The following locations have characteristic peaks: 10.6 ⁇ 0.2°, 16.3 ⁇ 0.2°, 19.5 ⁇ 0.2°, 21.5 ⁇ 0.2°, and 26.9 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the maleate salt of the compound of the formula A represented by the 2 ⁇ angle has characteristic peaks at the following positions: 7.0 ⁇ 0.2°, 10.6 ⁇ 0.2°, 13.6 ⁇ 0.2. °, 16.3 ⁇ 0.2 °, 19.5 ⁇ 0.2 °, 20.1 ⁇ 0.2 °, 21.5 ⁇ 0.2 °, 24.5 ⁇ 0.2 ° and 26.9 ⁇ 0.2 °.
  • the present invention provides a crystalline form of the maleate salt of the compound of formula A, the crystal form having an X-ray powder diffraction pattern represented by a 2 theta angle having characteristic peaks and relative intensities at:
  • a typical example of the crystalline form of the maleate salt of the compound of formula A has an X-ray powder diffraction (XRPD) pattern as shown in FIG.
  • the Fourier transform infrared spectroscopy of the crystalline form of the maleate salt of the compound of the formula A is 1734 cm -1 , 1574 cm -1 , 1485 cm -1 , 1439 cm -1 , 1364 cm -1 , 1346 cm -1 , 1080 cm - 1 , 1003 cm -1 , 893 cm -1 , 871 cm -1 , 757 cm -1 and 729 cm -1 have characteristic peaks.
  • the present invention provides a process for the preparation of a maleate salt of the compound of the formula A or a crystal form thereof, the process comprising the steps of: selecting an alcohol, a ketone, an ether (including a cyclic ether), In a solvent of an ester, water or a mixture thereof, a compound of the formula A and a maleic acid having a molar ratio of 1:1 to 1:5 are each formed into a suspension or a solution, and then mixed and reacted. After completion of the reaction, the solvent is removed and dried. .
  • the solvent is selected from the group consisting of ethanol, acetone, diethyl ether, water, ethyl acetate, 1,4-dioxane or a mixture thereof.
  • the molar ratio of the compound of the formula A to maleic acid is from 1:1.0 to 1:2.6.
  • the reaction is carried out at -10 to 60 ° C, more preferably at 10 ° C to 40 ° C; preferably, the reaction is carried out under stirring, and the stirring time is 10 to 72 hours, more preferably 10 to 24 hour.
  • the drying temperature is from 10 to 60 ° C, more preferably from 10 to 40 ° C.
  • the drying time is from 1 to 48 hours, more preferably from 1 to 24 hours.
  • the mass-to-volume ratio of the compound of the formula A to the solvent in the preparation method is 1 mg: 1 mL to 50 mg: 1 mL, more preferably 4 mg: 1 mL to 26 mg: 1 mL.
  • the maleate salt of the compound of the formula A of the present invention has a solubility in water of 16 ⁇ g/mL at 25 ° C, and the solubility in water is more obviously improved than that of the known compound of the formula A, which is better. Bioavailability.
  • the maleate salt of the compound of the formula A of the present invention has a solubility in water at 25 ° C of 16 ⁇ g / mL, a calcium salt of the compound of the formula A, a hydrochloride salt of the compound of the formula A, and a formula A.
  • the solubility in water is remarkably improved, and the bioavailability is good.
  • the maleate salt of the compound of the formula A of the present invention has a weight gain of 0.4% in a relative humidity range of 20% to 80%, and a potassium salt of the compound of the formula A and a calcium salt of the compound of the formula A.
  • a potassium salt of the compound of the formula A and a calcium salt of the compound of the formula A Compared with the conventional salt forms such as the hydrochloride salt of the compound of the formula A, the citrate of the compound of the formula A, the phosphate of the compound of the formula A, etc., it has a lower hygroscopic weight gain and thus can have a better Storage stability.
  • the crystalline form of the maleate salt of the compound of the formula A of the present invention is stable under an aqueous system, and therefore has a good application value in a wet granulation or suspension dosage form.
  • the crystalline form of the maleate salt of the compound of the formula A of the present invention is placed under normal, high temperature (60 ° C) and accelerated (40 ° C - 75% relative humidity) for 1 month, and its appearance, XRPD and melting point Not changing.
  • the crystal form of the maleate salt of the compound of the formula A of the present invention has good storage stability, and can better ensure the pharmaceutically active ingredient itself and the maleate or the crystal form thereof containing the compound of the formula A. Quality, safety, and stability issues in the formulation and/or storage of pharmaceutical formulations, such as impurity crystal forms, solubility differences, and the like.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the maleate salt of the compound of formula A and/or its crystalline form and optionally at least one pharmaceutically acceptable carrier or excipient.
  • the invention also provides the use of a maleate salt of the compound of formula A and/or its crystal form for the manufacture of a medicament for the treatment and/or prophylaxis of a disease or condition mediated by the SlP1 receptor.
  • the invention also provides a method for treating and/or preventing a disease or condition mediated by a SlP1 receptor, the method comprising administering to a subject in need thereof a compound of formula A provided herein.
  • a subject in need thereof a compound of formula A provided herein.
  • Maleate and/or its crystal form Preferably, the subject is a mammal; more preferably, the subject is a human.
  • the sodium salt of the compound of the formula A of the present invention in any method of preparing a maleate salt and a crystalline form of the maleate salt of the compound of formula A:
  • room temperature means a temperature of about 10 to 30 °C.
  • the "cyclic ether” may be tetrahydrofuran, 1,4-dioxane or the like.
  • the “stirring” may be carried out by a conventional method in the art, for example, the stirring method includes magnetic stirring, mechanical stirring, and the stirring speed is 50 to 1800 rpm, preferably 300 to 900 rpm.
  • solvent removal can be carried out by conventional methods in the art, such as filtration, volatilization, centrifugation, nitrogen blowing or spin drying.
  • the "filtration” is generally carried out by suction filtration at a pressure of less than atmospheric pressure at room temperature, preferably at a pressure of less than 0.09 MPa.
  • the "spin-drying method” generally performs steaming at a pressure less than atmospheric pressure, preferably at a pressure of less than 0.09 MPa; the “nitrogen blowing” generally allows nitrogen gas to be supplied through a nitrogen blowing device, and the liquid is volatilized and dried by rapid flow of nitrogen;
  • the specific operation of the “centrifugation” is: placing the sample to be separated into a centrifuge tube, for example, centrifuging at a rate of 6000 rpm until the solid is completely sunk to the bottom of the centrifuge tube; the specific operation of the "volatilization” is : The sample solution is volatilized at different temperatures until the solvent is dry.
  • the experimental temperature of the "solvent removal” is preferably from 10 to 60 °C.
  • the "drying” can be accomplished using conventional techniques in the art, such as drying at ambient temperature, blast drying or reduced pressure drying. It may be reduced in pressure or at normal pressure, and preferably the pressure is less than 0.09 MPa.
  • the drying apparatus and method are not limited and may be a fume hood, a blast oven, a spray dryer, a fluidized bed drying or a vacuum oven; it may be carried out under reduced pressure or no reduced pressure, preferably at a pressure of less than 0.09 MPa.
  • "crystal form&quot means that the compound is characterized by the X-ray powder diffraction pattern indicated, having a unique ordered molecular arrangement or configuration within the crystal lattice. It is well known to those skilled in the art that the experimental error therein depends on instrument conditions, sample preparation, and sample purity.
  • the 2 ⁇ angle of the peaks in the XRD pattern will typically vary slightly from instrument to sample. The difference in peak angle may vary by 1°, 0.8°, 0.5°, 03°, 0.1°, etc. depending on the instrument, and the error is usually ⁇ 0.2°, so the difference in peak angle cannot be the sole criterion.
  • the relative intensity of the peaks may vary with sample, sample preparation, and other experimental conditions, so the order of peak intensities cannot be the sole or decisive factor.
  • the influence of experimental factors such as sample height causes an overall shift in the peak angle, which usually allows a certain offset.
  • any crystal form having the same or similar characteristic peaks as the X-ray powder diffraction pattern of the present invention is within the scope of the present invention.
  • Single crystal form means a single crystal form as detected by X-ray powder diffraction.
  • novel salt forms of the compounds of formula A of the present invention are substantially pure, unitary, and are substantially free of any other crystalline or amorphous form.
  • substantially pure when used in reference to a new crystalline form means that the new crystalline form comprises at least 80% by weight of the compound present, more preferably at least 90% by weight, especially at least 95% ( Weight), especially at least 99% by weight.
  • the starting material of the present invention the compound of the formula A, can be obtained by referring to the preparation method of the patent document CN103450171A.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically and/or prophylactically effective amount of one or more of the salt forms of the present invention and/or its crystalline form and amorphous form or by the method of the present invention
  • the resulting salt form and/or its crystalline form and amorphous form are prepared, as well as optionally at least one pharmaceutically acceptable carrier or excipient.
  • the salt form of the compound of the formula A and the crystal form thereof include a sodium salt of the compound of the formula A, a crystal form of the sodium salt of the compound of the formula A, a sulfate of the compound of the formula A, a compound of the formula A
  • the crystalline form of the sulfate, the maleate of the compound of formula A and the crystalline form of the maleate of the compound of formula A may also comprise an amorphous form of the crystalline form or salt of another pharmaceutically acceptable salt or salt of the compound of formula A.
  • the above pharmaceutical composition may be formulated into a certain dosage form, preferably by oral administration, parenteral administration (including subcutaneous, intramuscular and intravenous), rectal administration, transdermal administration, buccal administration, nasal administration.
  • Dosage forms include, but are not limited to, solid dosage forms, liquid dosage forms, semi-liquid dosage forms, aerosols or suppositories.
  • dosage forms suitable for oral administration include tablets, capsules, granules, powders, pills, powders, lozenges, syrups or suspensions;
  • suitable forms for parenteral administration include aqueous or nonaqueous solutions or Emulsions;
  • dosage forms suitable for rectal administration include suppositories using hydrophilic or hydrophobic carriers;
  • dosage forms suitable for transdermal administration include ointments, creams;
  • formulations suitable for nasal administration include aerosols, sprays.
  • the above dosage forms may be adapted to the rapid release, delayed release or modified release of the active ingredient, as desired.
  • the pharmaceutically acceptable carrier of the present invention includes a solid carrier, and specifically includes, but not limited to, a diluent such as starch, pregelatinized starch, lactose, powdered cellulose, microcrystalline cellulose, calcium hydrogen phosphate, tricalcium phosphate.
  • a diluent such as starch, pregelatinized starch, lactose, powdered cellulose, microcrystalline cellulose, calcium hydrogen phosphate, tricalcium phosphate.
  • binders such as acacia, guar, gelatin, polyvinylpyrrolidone, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyethylene glycol, etc.
  • disintegration Agents such as starch, sodium starch glycolate, pregelatinized starch, crospovidone, croscarmellose sodium, colloidal silica, etc.
  • lubricants such as stearic acid, magnesium stearate, hard Zinc citrate, sodium benzoate, sodium acetate, etc.
  • glidants such as colloidal silica
  • complex forming agents such as various grades of cyclodextrins and resins
  • release rate controlling agents such as hydroxypropylcellulose, Hydroxymethyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, methyl cellulose, methyl methacrylate, wax, and the like.
  • the pharmaceutically acceptable carrier of the present invention further comprises a liquid carrier, and specifically includes, but not limited to, a solvent of an aqueous, oily or alcoholic solution such as sterile water, physiological saline solution, dextrose solution, mannitol solution, vegetable oil, cod liver oil. , ethanol, propanol, glycerin, etc. Further, a carrier such as polyethylene glycol or polypropylene glycol can also be used. Other pharmaceutically acceptable carriers may also be selected depending on the dosage form, including, but not limited to, film formers, plasticizers, colorants, flavoring agents, viscosity modifiers, preservatives, antioxidants, penetrants, buffers. Wait. Each carrier must be acceptable, compatible with the other ingredients in the formulation and not deleterious to the patient.
  • a solvent of an aqueous, oily or alcoholic solution such as sterile water, physiological saline solution, dextrose solution, mannitol solution, vegetable oil, cod liver oil.
  • the pharmaceutical composition can be prepared using methods well known to those skilled in the art.
  • the sodium salt of the compound of the formula A of the present invention, the crystalline form of the sodium salt of the compound of the formula A, the sulfate of the compound of the formula A, and the crystalline form of the sulfate of the compound of the formula A a maleate salt of a compound of formula A, a crystalline form of a maleate salt of a compound of formula A, or a combination thereof, in admixture with one or more pharmaceutically acceptable carriers, optionally, with a Or a mixture of various other pharmaceutically active ingredients.
  • the solid preparation can be prepared by a process such as mixing, granulation, or the like, and the liquid or semi-liquid dosage form can be prepared by a process of mixing, dissolving, dispersing, emulsifying, or the like.
  • the present invention provides a salt form of the present invention and/or its crystal form and amorphous form or a salt form obtained by the production method of the present invention and/or its crystal form and amorphous form are prepared for treatment and/or prevention by S1P1. Use in a drug that mediates a disease or condition.
  • the salt form and its crystalline form and amorphous form comprise a sodium salt of a compound of formula A, a crystalline form of a sodium salt of a compound of formula A, a sulfate of a compound of formula A, a sulfuric acid of a compound of formula A,
  • the disease or condition mediated by the S1P1 receptor is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, autoimmune disease, chronic inflammatory disease, asthma, inflammatory neuropathy, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosus, psoriasis, ischemia-reperfusion injury, solid tumors, angiogenesis-related diseases, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel diseases, insulin and Non-insulin dependent diabetes and other related immune diseases; preferably, the disease or condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and psoriasis.
  • the present invention provides a method of treating and/or preventing a disease or condition mediated by an S1P1 receptor, the method comprising administering to a subject in need thereof a therapeutically and/or prophylactically effective amount of a salt of the present invention and/or Or a crystalline form thereof, or a combination thereof, or a pharmaceutical composition thereof, wherein the salt and its crystalline form and amorphous form comprise a sodium salt of a compound of formula A, a crystalline form of a sodium salt of a compound of formula A, and formula A
  • the disease or condition mediated by the S1P1 receptor is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, autoimmune disease, chronic inflammatory disease, asthma, inflammatory neuropathy, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosus, psoriasis, ischemia-reperfusion injury, solid tumors, angiogenesis-related diseases, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel diseases, insulin and Non-insulin dependent diabetes and other related immune diseases; preferably, the disease or condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and psoriasis.
  • Such subjects include, but are not limited to, mammals.
  • the crystalline forms and amorphous forms provided by the present invention, or combinations thereof, or pharmaceutical compositions thereof, can be co-administered with other therapies or therapeutic agents.
  • the dose of the compound or pharmaceutical composition required to effect a therapeutic, prophylactic or ameliorating effect will generally depend on the particular compound being administered, the patient, the particular disease or condition and its severity, the route and frequency of administration, and the like, and The division judges according to the specific circumstances.
  • Figure 1 is an IR spectrum of the sodium salt of the compound of Formula A of Example 3 of the present invention.
  • Figure 3 is a TGA spectrum of the sodium salt of the compound of Formula A of Example 3 of the present invention.
  • Figure 4 is a DSC chart of the sodium salt of the compound of Formula A of Example 3 of the present invention.
  • Figure 5 is an IR spectrum of the sulfate salt of the compound of Formula A of Example 13 of the present invention.
  • Figure 6 is an XRPD pattern of the sulfate salt of the compound of Formula A of Example 13 of the present invention.
  • Figure 7 is a TGA pattern of the sulfate salt of the compound of Formula A of Example 13 of the present invention.
  • Figure 8 is a DSC chart of the sulfate salt of the compound of Formula A of Example 13 of the present invention.
  • Figure 9 is an IR spectrum of the maleate salt of the compound of Formula A of Example 21 of the present invention.
  • Figure 10 is an XRPD pattern of the maleate salt of the compound of Formula A of Example 21 of the present invention.
  • Figure 11 is a TGA pattern of the maleate salt of the compound of Formula A of Example 21 of the present invention.
  • Figure 12 is a DSC chart of the maleate salt of the compound of Formula A of Example 21 of the present invention.
  • X-ray powder diffraction (XPRD): The instrument was a Bruker D8 Advance diffractometer. The samples were tested at room temperature. The detection conditions are as follows, the angle range is 3 to 40 ° 2 ⁇ , the step size is 0.02 ° 2 ⁇ , and the speed is 0.2 second / step.
  • DSC Differential thermal analysis
  • Thermogravimetric analysis (TGA) data was taken from the TA Instruments Q500 TGA.
  • the detection method is as follows: 5 to 15 mg of the sample is placed in a platinum crucible, and the sample is raised from room temperature to 300 by a stepwise high-resolution detection method at a heating rate of 10 ° C/min under the protection of 40 mL/min dry N 2 . °C.
  • Infrared spectroscopy (IR) data was taken from Bruker Tensor 27, and instrument control software and data analysis software were OPUS.
  • the infrared absorption spectrum is usually collected in the range of 600 to 4000 cm -1 using an ATR apparatus.
  • Dynamic moisture adsorption analysis (DVS) data and isothermal adsorption analysis data were taken from the TA Instruments Q5000 TGA.
  • the detection method is as follows: 1 to 10 mg of the sample is placed in a platinum crucible, and the change in weight during the change of the relative humidity from 20% to 80% is detected.
  • HPLC solubility data was taken from an Agilent 1260 high performance liquid chromatograph.
  • the column was Poroshell 120 EC-C18 (2.7*50 mm, 4.6 ⁇ m), the detection wavelength was 254 nm, the column temperature was 40 ° C, the flow rate was 1.5 mL/min, and the injection volume was 5 ⁇ L.
  • the sample was dissolved in the mobile phase B, and the sample solution was set to a concentration of about 0.45 mg/mL, and the sample concentration was measured by the following gradient method.
  • ion chromatograph (IC) data was taken from Dionex ICS-900, and the workstation and analysis software were all Chromeleon Console.
  • the external standard method was used for ion content detection.
  • the ultrasonic operation in the examples facilitated dissolution of the sample and the apparatus was an ultrasonic cleaner operated at 40 kHz for 15 minutes.
  • the compound of the formula A can be obtained by referring to the production method of the example 2 of the patent document CN103450171A.
  • Acetone and water are used as the reaction solvent, and the salt of the compound of the formula A and the molar ratio of the ion to 1:1.2 are selected, and the salt ratio of the compound is determined by IC to prepare the citrate of the compound of the formula A, and the formula A is prepared.
  • the IC characterization showed that the sodium salt of the compound of formula A was a salt of the compound of formula A and the sodium ion was reacted in a molar ratio of 1:1.
  • the IC characterization showed that the sodium salt of the compound of formula A was a salt of the compound of formula A and the sodium ion was reacted in a molar ratio of 1:1.
  • the IC characterization showed that the sodium salt of the compound of formula A was a salt of the compound of formula A and the sodium ion was reacted in a molar ratio of 1:1.
  • the IC characterization showed that the sodium salt of the compound of formula A was a salt of the compound of formula A and the sodium ion was reacted in a molar ratio of 1:1.
  • the IC characterization showed that the sodium salt of the compound of formula A was a salt of the compound of formula A and the sodium ion was reacted in a molar ratio of 1:1.
  • the IC characterization showed that the sodium salt of the compound of formula A was a salt of the compound of formula A and the sodium ion was reacted in a molar ratio of 1:1.
  • the IC characterization showed that the sodium salt of the compound of formula A was a salt of the compound of formula A and the sodium ion was reacted in a molar ratio of 1:1.
  • the IC characterization showed that the sodium salt of the compound of formula A was a salt of the compound of formula A and the sodium ion was reacted in a molar ratio of 1:1.
  • the IC characterization showed that the sodium salt of the compound of formula A was a salt of the compound of formula A and the sodium ion was reacted in a molar ratio of 1:1.
  • the IC characterization showed that the sodium salt of the compound of formula A was a salt of the compound of formula A and the sodium ion was reacted in a molar ratio of 1:1.
  • the IC characterization showed that the sulfate of the compound of formula A was a compound of formula A and sulfuric acid was reacted to form a salt in a molar ratio of 2:1.
  • the IC characterization showed that the sulfate of the compound of formula A was a compound of formula A and sulfuric acid was reacted to form a salt in a molar ratio of 2:1.
  • the IC characterization showed that the sulfate of the compound of formula A was a compound of formula A and sulfuric acid was reacted to form a salt in a molar ratio of 2:1.
  • the IC characterization showed that the sulfate of the compound of formula A was a compound of formula A and sulfuric acid was reacted to form a salt in a molar ratio of 2:1.
  • the IC characterization showed that the sulfate of the compound of formula A was a compound of formula A and sulfuric acid was reacted to form a salt in a molar ratio of 2:1.
  • the IC characterization showed that the sulfate of the compound of formula A was a compound of formula A and sulfuric acid was reacted to form a salt in a molar ratio of 2:1.
  • the IC characterization showed that the sulfate of the compound of formula A was a compound of formula A and sulfuric acid was reacted to form a salt in a molar ratio of 2:1.
  • the IC characterization showed that the sulfate of the compound of formula A was a compound of formula A and sulfuric acid was reacted to form a salt in a molar ratio of 2:1.
  • the IC characterization showed that the sulfate of the compound of formula A was a compound of formula A and sulfuric acid was reacted to form a salt in a molar ratio of 2:1.
  • the solid was beaten with 0.2 mL of 1,4-dioxane:water (1:1) for 1 hour, then centrifuged, and the solid was dried under vacuum at 40 ° C for 48 hours. Sulfate of the compound of formula A of the invention.
  • the IC characterization showed that the sulfate of the compound of formula A was a compound of formula A and sulfuric acid was reacted to form a salt in a molar ratio of 2:1.
  • the IC characterization showed that the maleate salt of the compound of formula A was a salt of the compound of formula A and maleic acid at a molar ratio of 1:1.
  • the maleate XRD pattern is shown in Figure 10.
  • the maleate TGA pattern is shown in Figure 11.
  • the maleate salt DSC chart is shown in FIG.
  • the IC characterization showed that the maleate salt of the compound of formula A was a salt of the compound of formula A and maleic acid at a molar ratio of 1:1.
  • the IC characterization showed that the maleate salt of the compound of formula A was a salt of the compound of formula A and maleic acid at a molar ratio of 1:1.
  • the IC characterization showed that the maleate salt of the compound of formula A was a salt of the compound of formula A and maleic acid at a molar ratio of 1:1.
  • the IC characterization showed that the maleate salt of the compound of formula A was a salt of the compound of formula A and maleic acid at a molar ratio of 1:1.
  • the IC characterization showed that the maleate salt of the compound of formula A was a salt of the compound of formula A and maleic acid at a molar ratio of 1:1.
  • the IC characterization showed that the maleate salt of the compound of formula A was a salt of the compound of formula A and maleic acid at a molar ratio of 1:1.
  • the IC characterization showed that the maleate salt of the compound of formula A was a salt of the compound of formula A and maleic acid at a molar ratio of 1:1.
  • the IC characterization showed that the maleate salt of the compound of formula A was a salt of the compound of formula A and maleic acid at a molar ratio of 1:1.
  • the sodium salt of the compound of the formula A of the present invention is subjected to an aqueous solubility test, and the specific operation is as follows: 5 mg of the sodium salt of the compound of the formula A of the present invention is placed in a 20 ml glass bottle, and deionized water is gradually added dropwise at 25 ° C. Ultrasound to dissolve. Calculate the solubility of the sample in water.
  • the sodium salt of the compound of the formula A of the present invention has a high solubility and thus can have a better bioavailability.
  • the conventional salt (citrate of the compound of the formula A, the phosphate of the compound of the formula A, the hydrochloride of the compound of the formula A) is subjected to DSC and TGA analysis. The melting point and decomposition temperature data of each salt type are obtained.
  • the sodium salt of the compound of the formula A of the present invention is a conventional salt (the citrate of the compound of the formula A, the phosphate of the compound of the formula A, the hydrochloride of the compound of the formula A) It has a very high melting point and decomposition temperature and thus has better thermal stability.
  • a conventional salt (calcium salt of the compound of formula A, citrate of the compound of formula A, phosphate of the compound of formula A, hydrochloric acid of the compound of formula A) Salt
  • the sulfate of the compound of the formula A of the present invention and the maleate of the compound of the formula A are subjected to an aqueous solubility test, and the specific operation is as follows: 5 mg of the compound of the formula A is known as a free form, a conventional salt.
  • a calcium salt of a compound represented by A a citrate salt of a compound of formula A, a phosphate of a compound of formula A, a hydrochloride salt of a compound of formula A), a sulfuric acid of a compound of formula A prepared by the present invention.
  • the salt and the maleate salt of the compound of formula A were placed in a 20 mL glass vial, and 15 mL of deionized water was added and stirred at 25 ° C for 2 hours. Sampling and filtration, HPLC detection of concentration. Calculate the solubility of the active ingredient in the sample in water.
  • the sulfate of the compound of the formula A of the present invention and the maleate of the compound of the formula A are improved in solubility in water at 25 ° C by about 10 to 20 times compared with the free state of the compound of the formula A.
  • 25 ° C water Compared with other conventional salts (calcium salt of the compound of formula A, citrate of compound of formula A, phosphate of compound of formula A, hydrochloride of compound of formula A), 25 ° C water
  • the solubility is increased by about 3 to 8 times, and the solubility is better, so that it has better bioavailability.
  • a conventional salt (a potassium salt of the compound of the formula A, a calcium salt of the compound of the formula A, a compound of the formula A)
  • the citrate, the phosphate of the compound of the formula A, the hydrochloride of the compound of the formula A) were subjected to DVS analysis to obtain hygroscopicity data for each salt type.
  • Table 5 shows the sulfate salt of the compound of the formula A of the present invention and the maleate salt of the compound of the formula A and a conventional salt (potassium salt of the compound of the formula A, calcium salt of the compound of the formula A, formula)
  • the citrate salt of the compound represented by A, the phosphate of the compound of the formula A, the hydrochloride salt of the compound of the formula A) has a lower moisture absorption weight and thus has better storage stability and can be more Good avoidance of quality, safety and stability issues during drug manufacturing and/or storage.
  • the crystal form of the sulfate salt of the compound of the formula A of the present invention and the crystal form of the maleate salt of the compound of the formula A are subjected to a stability test, and the specific operation is as follows: the compound of the formula A prepared by the present invention is separately obtained.
  • the crystalline form of the sulfate and the crystalline form of the maleate salt of the compound of formula A were placed in a conventional (25 ° C sealed and protected from light), high temperature (60 ° C sealed and protected from light) and accelerated (40 ° C -
  • the crystal form stability was examined under conditions of 75% relative humidity and exposed to light for 30 days.
  • the crystalline form of the sodium salt of the compound of the formula A of the present invention, the crystalline form of the sulfate of the compound of the formula A, and the crystalline form of the maleate of the compound of the formula A are formed into a suspension in the solvent of Table 7.
  • the mixture was stirred at room temperature for 3 days to examine the stability of the crystal form, and compared with the result of Comparative Example 1 in the patent CN105315266A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/CN2018/085617 2018-05-04 2018-05-04 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 Ceased WO2019210511A1 (zh)

Priority Applications (22)

Application Number Priority Date Filing Date Title
BR112020022429-4A BR112020022429B1 (pt) 2018-05-04 Forma cristalina do maleato de agonista de receptor s1p1, seu método de preparação, seu uso e composição farmacêutica que o compreende
JP2021510499A JP7275253B2 (ja) 2018-05-04 2018-05-04 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
SG11202010969UA SG11202010969UA (en) 2018-05-04 2018-05-04 Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
PCT/CN2018/085617 WO2019210511A1 (zh) 2018-05-04 2018-05-04 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
CA3099196A CA3099196A1 (en) 2018-05-04 2018-05-04 Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
EP18917186.1A EP3792258B1 (en) 2018-05-04 2018-05-04 Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
NZ770323A NZ770323A (en) 2018-05-04 2018-05-04 Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
IL278464A IL278464B2 (en) 2018-05-04 2018-05-04 Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
MX2020011665A MX2020011665A (es) 2018-05-04 2018-05-04 Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica.
AU2018421487A AU2018421487B2 (en) 2018-05-04 2018-05-04 Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
EP24155906.1A EP4353719B1 (en) 2018-05-04 2018-05-04 Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
US17/052,160 US11512078B2 (en) 2018-05-04 2018-05-04 Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
ES18917186T ES2978392T3 (es) 2018-05-04 2018-05-04 Sal de adición del agonista del receptor S1P1 y forma cristalina de la misma, y composición farmacéutica
KR1020207034174A KR102672632B1 (ko) 2018-05-04 2018-05-04 S1p1 수용체 작용제의 부가 염 및 이의 결정 형태 및 약제학적 조성물
IL312512A IL312512B2 (en) 2018-05-04 2018-05-04 S1P1 receptor agonist, its salt, its crystalline form, and its pharmaceutical composition
KR1020247018420A KR20240094023A (ko) 2018-05-04 2018-05-04 S1p1 수용체 작용제의 부가 염 및 이의 결정 형태 및 약제학적 조성물
ZA2020/07347A ZA202007347B (en) 2018-05-04 2020-11-25 Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
US17/961,270 US12202822B2 (en) 2018-05-04 2022-10-06 Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
JP2023023091A JP7651198B2 (ja) 2018-05-04 2023-02-17 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
US18/977,539 US20250320200A1 (en) 2018-05-04 2024-12-11 Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
JP2025035420A JP2025074350A (ja) 2018-05-04 2025-03-06 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
IL323665A IL323665A (en) 2018-05-04 2025-09-29 S1P1 receptor agonist, its salt, crystalline form, and pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/085617 WO2019210511A1 (zh) 2018-05-04 2018-05-04 一种s1p1受体激动剂的加成盐及其晶型和药物组合物

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/052,160 A-371-Of-International US11512078B2 (en) 2018-05-04 2018-05-04 Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
US17/961,270 Division US12202822B2 (en) 2018-05-04 2022-10-06 Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition

Publications (1)

Publication Number Publication Date
WO2019210511A1 true WO2019210511A1 (zh) 2019-11-07

Family

ID=68387039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/085617 Ceased WO2019210511A1 (zh) 2018-05-04 2018-05-04 一种s1p1受体激动剂的加成盐及其晶型和药物组合物

Country Status (13)

Country Link
US (3) US11512078B2 (https=)
EP (2) EP4353719B1 (https=)
JP (3) JP7275253B2 (https=)
KR (2) KR20240094023A (https=)
AU (1) AU2018421487B2 (https=)
CA (1) CA3099196A1 (https=)
ES (1) ES2978392T3 (https=)
IL (3) IL312512B2 (https=)
MX (1) MX2020011665A (https=)
NZ (1) NZ770323A (https=)
SG (1) SG11202010969UA (https=)
WO (1) WO2019210511A1 (https=)
ZA (1) ZA202007347B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022099155A1 (en) * 2020-11-09 2022-05-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ770323A (en) * 2018-05-04 2025-12-19 Suzhou Connect Biopharmaceuticals Ltd Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103450171A (zh) 2013-09-22 2013-12-18 苏州康乃德生物医药有限公司 一种免疫调节新型化合物、其用途和包含其的药物组合物
CN105315266A (zh) 2014-08-01 2016-02-10 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型
CN108299412A (zh) * 2017-01-11 2018-07-20 苏州康乃德生物医药有限公司 一种s1p1受体激动剂的加成盐及其晶型和药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
CN105348276B (zh) 2014-08-22 2020-05-26 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法
NZ770323A (en) * 2018-05-04 2025-12-19 Suzhou Connect Biopharmaceuticals Ltd Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103450171A (zh) 2013-09-22 2013-12-18 苏州康乃德生物医药有限公司 一种免疫调节新型化合物、其用途和包含其的药物组合物
CN105315266A (zh) 2014-08-01 2016-02-10 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型
CN108299412A (zh) * 2017-01-11 2018-07-20 苏州康乃德生物医药有限公司 一种s1p1受体激动剂的加成盐及其晶型和药物组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022099155A1 (en) * 2020-11-09 2022-05-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Also Published As

Publication number Publication date
KR20240094023A (ko) 2024-06-24
JP2025074350A (ja) 2025-05-13
ES2978392T3 (es) 2024-09-11
SG11202010969UA (en) 2020-12-30
IL278464A (https=) 2021-03-01
EP4353719B1 (en) 2025-12-24
JP2023062091A (ja) 2023-05-02
KR102672632B1 (ko) 2024-06-07
EP3792258A4 (en) 2021-10-06
EP3792258A1 (en) 2021-03-17
IL278464B1 (en) 2024-06-01
IL323665A (en) 2025-11-01
KR20210019999A (ko) 2021-02-23
US12202822B2 (en) 2025-01-21
MX2020011665A (es) 2021-01-20
US20210230152A1 (en) 2021-07-29
BR112020022429A2 (pt) 2021-02-09
US20250320200A1 (en) 2025-10-16
IL278464B2 (en) 2024-10-01
IL312512A (en) 2024-07-01
JP2021532165A (ja) 2021-11-25
US20230050777A1 (en) 2023-02-16
EP4353719A1 (en) 2024-04-17
IL312512B2 (en) 2026-03-01
IL312512B1 (en) 2025-11-01
ZA202007347B (en) 2021-10-27
EP3792258B1 (en) 2024-02-07
AU2018421487B2 (en) 2024-09-12
JP7275253B2 (ja) 2023-05-17
JP7651198B2 (ja) 2025-03-26
AU2018421487A1 (en) 2020-12-17
CA3099196A1 (en) 2019-11-07
NZ770323A (en) 2025-12-19
US11512078B2 (en) 2022-11-29

Similar Documents

Publication Publication Date Title
US11286259B2 (en) Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
US20250320200A1 (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
WO2018103027A1 (zh) 替吡法尼的晶型及其制备方法及药物组合物
CN112778290B (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
TWI662031B (zh) １－｛２－氟－４－［５－（４－異丁基苯基）－１，２，４－噁二唑－３－基］－苄基｝－３－吖丁啶羧酸的晶型
CN105461610A (zh) 一种阿普斯特的晶型及其制备方法、药物组合物和用途
RU2822288C2 (ru) Соль присоединения агониста рецептора s1p1 и ее кристаллическая форма и фармацевтическая композиция на ее основе
HK40106546B (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
US10759798B2 (en) ABT-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof
HK40106546A (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
HK40042284B (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
HK40042284A (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18917186

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021510499

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3099196

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 122022025293

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020022429

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20207034174

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018421487

Country of ref document: AU

Date of ref document: 20180504

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018917186

Country of ref document: EP

Effective date: 20201204

ENP Entry into the national phase

Ref document number: 112020022429

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20201103

WWG Wipo information: grant in national office

Ref document number: 11202010969U

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202010969U

Country of ref document: SG

WWD Wipo information: divisional of initial pct application

Ref document number: 323665

Country of ref document: IL

WWG Wipo information: grant in national office

Ref document number: 770323

Country of ref document: NZ